MESENTECH

Mesentech is developing innovative drugs that can selectively distribute to musculoskeletal tissue. These drugs carry payloads such as small-molecule hormones or anti-cancer agents... Mesentech was founded by Dr. Robert Young, who led teams that discovered SingulAir, Vioxx, Arcoxia, ondanacatib, among others while leading medicinal chemistry at Merck. MES1022 is a clinical stage compound that regenerates muscle and bone with selective distribution to musculoskeletal compartments. It shows promise in treatment of muscle atrophy in muscular dystrophies. MES3015 is an anti cancer agent that selectively distributes to bone... Mesentech has developed novel chemistry that selectively delivers pharmaceuticals to a specific tissue. The advantage of our technology is that exposure to the active pharmaceutical occurs only in the targeted tissues, thereby eliminating toxicity to unrelated organs.

Primary location: Vancouver Canada